Latest News from: Dana-Farber Cancer Institute

Filters close
26-Oct-2021 8:05 AM EDT
Survival similar for younger and older patients with metastatic colorectal cancer, study finds
Dana-Farber Cancer Institute

Even though young patients with metastatic colorectal cancer tend to be more fit and receive more intensive treatment than older patients, both groups survive for roughly the same amount of time, according to a new study by Dana-Farber Cancer Institute investigators.

Newswise: Targeted drug shows activity against brain metastases in kidney cancer
20-Oct-2021 4:05 PM EDT
Targeted drug shows activity against brain metastases in kidney cancer
Dana-Farber Cancer Institute

A targeted drug has shown promising activity against brain metastases resulting from kidney cancer, achieving a 50 percent response rate, and supporting further studies of the drug in this patient group whose poor prognosis has created a significant unmet need.

17-Sep-2021 9:00 AM EDT
Antibody-drug conjugate shows impressive activity in patients with non-small cell lung cancer with mutation in HER2 gene
Dana-Farber Cancer Institute

More than half of patients with non-small cell lung cancer (NSCLC) bearing a mutation in the HER2 gene had their tumors stop growing or shrink for an extended time after treatment with a drug that hitches a chemotherapy agent to a highly targeted antibody, an international clinical trial led by investigators at Dana-Farber Cancer Institute has found.

16-Aug-2021 8:00 AM EDT
Vitamin D May Protect Against Young-Onset Colorectal Cancer
Dana-Farber Cancer Institute

Consuming higher amounts of Vitamin D – mainly from dietary sources – may help protect against developing young-onset colorectal cancer or precancerous colon polyps, according to the first study to show such an association.

Released: 9-Aug-2021 3:05 PM EDT
Prostate cancer partnership honored for statistical excellence in accelerating therapeutic advances
Dana-Farber Cancer Institute

The Intermediate Clinical Endpoints of Cancer of the Prostate (ICECaP) working group, led by Dana-Farber Cancer Institute researchers, is being honored by the American Statistical Association (ASA) with the 2021 Statistical Partnerships Among Academe, Industry, and Government (SPAIG) Award.

Released: 2-Aug-2021 8:30 AM EDT
Dana-Farber Launches New Podcast Series, Unraveled
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute is launching a new podcast series, titled Unraveled, to explain the science behind some of the most important breakthroughs in cancer research.

Released: 27-Jul-2021 12:05 AM EDT
Dana-Farber Brigham Cancer Center is ranked the best in New England
Dana-Farber Cancer Institute

Dana-Farber Brigham Cancer Center is ranked #4 as a Best Hospital for cancer care by U.S. News and World Report for 2021-22

22-Jun-2021 2:25 PM EDT
New Research Uncovers How Cancers with Common Gene Mutation Develop Resistance to Targeted Drugs
Dana-Farber Cancer Institute

A new study by Dana-Farber Cancer Institute researchers has given scientists their first look at the genomic landscape of tumors that have grown resistant to drugs targeting the abnormal KRASG12C protein. Their work shows that, far from adopting a common route to becoming resistant, the cells take a strikingly diverse set of avenues, often several at a time. The findings, reported online today in the New England Journal of Medicine, underscore the need for new drugs that inhibit KRAS differently than current agents do.

15-Jun-2021 11:40 AM EDT
Antibiotic Novobiocin Found to Kill Tumor Cells with DNA-Repair Glitch
Dana-Farber Cancer Institute

An antibiotic developed in the 1950s and largely supplanted by newer drugs, effectively targets and kills cancer cells with a common genetic defect, laboratory research by Dana-Farber Cancer Institute scientists shows. The findings have spurred investigators to open a clinical trial of the drug, novobiocin, for patients whose tumors carry the abnormality.

3-Jun-2021 4:45 PM EDT
Immunotherapy drug delays recurrence in kidney cancer patients
Dana-Farber Cancer Institute

Treatment with an immunotherapy drug following kidney cancer surgery, prolonged disease-free survival rates in patients at high risk for recurrence, according to an interim report of a phase 3 clinical trial of adjuvant immunotherapy in this patient population.

Released: 27-May-2021 2:30 PM EDT
Survival benefits of immunotherapy combination persist for more than six years in patients with advanced melanoma
Dana-Farber Cancer Institute

In the longest follow-up results from a clinical trial of combination immunotherapy for metastatic melanoma, investigators report that nearly half the patients who received the drugs nivolumab and ipilimumab were alive a median of six and a half years after treatment.

19-May-2021 4:05 PM EDT
Immunotherapy combination shows benefit for patients with advanced melanoma, phase 3 trial shows
Dana-Farber Cancer Institute

A combination of two drugs that target different proteins on immune system T cells kept advanced melanoma in check significantly longer than one of the drugs alone in a phase 3 clinical trial involving 714 patients. Dana-Farber Cancer Institute investigators co-led the study.

19-May-2021 4:30 PM EDT
Dana-Farber researchers present key studies at ASCO annual meeting
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute researchers are presenting dozens of research studies at the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO). The studies will be presented during the virtual program on June 4-8, 2021. ASCO is the world’s largest clinical cancer research meeting, attracting more than 30,000 oncology professionals from around the world.

18-May-2021 8:05 AM EDT
“45 Is the New 50” as Age for Colorectal Cancer Screening Is Lowered
Dana-Farber Cancer Institute

Prompted by a recent alarming rise in cases of colorectal cancer in people younger than 50, an independent expert panel has recommended that individuals of average risk for the disease begin screening exams at 45 years of age instead of the traditional 50. “A concerning increase in colorectal cancer incidence among younger individuals (ie, younger than 50 years; defined as young-onset colorectal cancer) has been documented since the mid-1990s, with 11% of colon cancers and 15% of rectal cancers in 2020 occurring among patients younger than 50 years, compared with 5% and 9%, respectively, in 2010,” said Kimmie Ng, MD, MPH, first author of an editorial in JAMA accompanying the article about the guideline change of the USPSTF.

Released: 5-May-2021 9:30 AM EDT
Heidi E. Conway joins Dana-Farber to lead Human Resources Department
Dana-Farber Cancer Institute

New Human Resources and Chief People Officer named at Dana-Farber Cancer Institute.

26-Apr-2021 1:45 PM EDT
For young patients with breast cancer, fertility concerns influence endocrine therapy decisions, study finds
Dana-Farber Cancer Institute

Concerns about fertility often influence how young women with breast cancer approach treatment decisions and are a reason for forgoing or delaying hormone-blocking therapy, a new study by Dana-Farber Cancer Institute investigators shows.

Released: 23-Apr-2021 8:45 AM EDT
Dana-Farber Cancer Institute faculty recognized as 2021 ASCO leaders in cancer care
Dana-Farber Cancer Institute

The American Society of Clinical Oncology (ASCO) recognized two Dana-Farber Cancer Institute researchers as winners of ASCO's Special Awards, the Society’s highest honors. The recipients of these awards have worked to transform cancer care around the world.

Released: 20-Apr-2021 8:05 AM EDT
Dana-Farber nurses present research at 2021 Oncology Nursing Society Congress
Dana-Farber Cancer Institute

Dana-Farber Cancer Institute researchers are presenting key studies at the 46th Annual Oncology Nursing Society (ONS) Congress. The presentations focus on the effects of the COVID-19 crisis, the need for diversity, equity and inclusion in oncology nursing as well as the critical role oncology nurse navigators play in a patient’s treatment plan.

26-Mar-2021 3:15 PM EDT
Expert panel issues recommendations for addressing cancer inequities
Dana-Farber Cancer Institute

Expert panel issues recommendations for addressing cancer inequities

19-Mar-2021 5:05 PM EDT
Study underscores need for multidisciplinary care for COVID-19 long-haulers
Dana-Farber Cancer Institute

A comprehensive review published today in Nature Medicine offers an initial glimpse of the multi-organ effects of long-term COVID-19 and suggests a framework for the care of COVID-19 long-haulers through dedicated, multidisciplinary clinics.



close
0.13592